| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net (loss) income | ||||||
-427 | 1,055 | -584 | -434 | -130 | ||
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||
Depreciation | ||||||
621 | 537 | - | - | - | ||
Bad debt expense | ||||||
69 | 0 | - | - | - | ||
Deferred finance charge amortization | ||||||
1 | 0 | - | - | - | ||
Provision for deferred income taxes | ||||||
1,098 | 0 | - | - | - | ||
Interest income on cash and investments held in trust account | ||||||
- | - | -216 | -108 | 0 | ||
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
5,309 | -1,071 | - | - | - | ||
Expenses paid by related parties via transfer of common stock | ||||||
- | - | 31 | - | 0 | ||
Stock compensation | ||||||
- | - | - | 36 | - | ||
Amortization of deferred financing costs | ||||||
- | - | 46 | 0 | - | ||
Prepaid expenses | ||||||
201 | 0 | - | -27 | -16 | ||
Costs and estimated earnings in excess of billings | ||||||
553 | 314 | - | - | - | ||
Accounts payable | ||||||
2,778 | -707 | - | - | - | ||
Accrued expenses | ||||||
-117 | -87 | - | - | - | ||
Billings in excess of costs and estimated earnings on uncompleted contracts | ||||||
-54 | -73 | - | - | - | ||
Accrued losses on contract in progress | ||||||
9 | -9 | - | - | - | ||
Deferred compensation | ||||||
-27 | 143 | - | - | - | ||
Changes in prepaid insurance and other | ||||||
- | - | -22 | - | - | ||
Changes in accounts payable and accrued expenses | ||||||
- | - | 301 | 106 | -4 | ||
Net cash (used in) provided by operating activities | ||||||
-2,130 | 1,634 | -399 | -371 | -118 | ||
Cash flows from investing activities: | ||||||
Purchase of solar arrays and equipment | ||||||
39 | 2,729 | - | - | - | ||
Cash surrender value - life insurance | ||||||
224 | -83 | - | - | - | ||
Investment costs | ||||||
129 | 0 | - | - | - | ||
Investment in captive insurance | ||||||
60 | 44 | - | - | - | ||
Investment in restricted cash and investments | ||||||
- | - | - | 40,473 | 0 | ||
Proceeds from principal repayments from restricted investments | ||||||
- | - | - | 0 | - | ||
Distribution from trust account for franchise taxes | ||||||
- | - | - | 0 | - | ||
Interest income on cash and investments held in trust account | ||||||
- | - | -216 | -108 | 0 | ||
Net cash used in investing activities | ||||||
-4 | -2,857 | 216 | -40,365 | 0 | ||
Cash flows from financing activities: | ||||||
Net borrowings on line of credit | ||||||
2,212 | 972 | - | - | - | ||
Proceeds from long-term debt | ||||||
9 | 930 | - | - | - | ||
Proceeds from note payable - stockholders and affiliates | ||||||
- | - | 809 | 428 | 246 | ||
Proceeds from sale of units in IPO, net of offering costs | ||||||
- | - | - | 37,687 | 0 | ||
Proceeds from private placement of units, net of offering costs | ||||||
- | - | - | 2,620 | 0 | ||
Deferred finance charges | ||||||
21 | 0 | 26 | 0 | - | ||
Payments of long-term debt | ||||||
-347 | -387 | - | - | - | ||
Payments to stockholders | ||||||
295 | -245 | - | - | - | ||
Equity line issuance costs | ||||||
10 | 0 | - | - | - | ||
Stockholder distributions paid | ||||||
219 | 493 | - | - | - | ||
Payments for deferred offering costs | ||||||
- | - | - | - | 85 | ||
Principal payments on short-term loan | ||||||
- | - | 30 | 33 | 16 | ||
Proceeds from sale of common stock to initial stockholders | ||||||
- | - | - | - | 0 | ||
Net cash provided by (used in) financing activities | ||||||
1,917 | 775 | 752 | 40,702 | 144 | ||
Net decrease in cash | ||||||
-217 | -447 | 569 | - | - | ||
Proceeds from Company's public offering recorded as common shares subject to possible redemption | ||||||
- | - | -533 | - | - | ||
Refinancing of prepaid insurance loan | ||||||
- | - | - | -13 | 0 | ||
Loan for prepaid insurance | ||||||
- | - | - | - | 0 | ||
Offering costs included in accounts payable and accrued expenses | ||||||
- | - | - | 52 | 66 | ||
Cost for underwriter option included as reduction in accounts payable due to underwriter | ||||||
- | - | - | 0 | 0 | ||
Proceeds from the Company's public offering recorded as common shares subject to possible redemption | ||||||
- | - | - | -33,666 | 0 | ||
Deferred underwriter commission | ||||||
- | - | - | -780 | 0 | ||
Deferred financing costs in accounts payable | ||||||
- | - | 63 | 0 | - | ||
Financing costs paid by related parties via transfer of common stock | ||||||
- | - | 19 | 0 | - | ||
Loan for prepaid insurance | ||||||
- | - | 30 | 47 | 16 | ||
Interest | ||||||
244 | 134 | 0 | 0 | - | ||
Income taxes | ||||||
5 | 0 | - | - | - | ||
Net increase (decrease) in cash and restricted cash | ||||||
- | - | - | -34 | 25 | ||
Supplemental schedule of non-cash investing and financing activities: | ||||||
Vehicles purchased and financed | ||||||
126 | 189 | - | - | - | ||
Shares of Common Stock issued for equity line, at par | ||||||
0 | 0 | - | - | - | ||
Accrued S corporation distributions which have not been paid | ||||||
266 | 0 | - | - | - | ||
Interest paid | ||||||
- | - | - | - | 0 | ||